CN109311891B - 作为jak抑制剂的吡咯并嘧啶化合物的结晶 - Google Patents
作为jak抑制剂的吡咯并嘧啶化合物的结晶 Download PDFInfo
- Publication number
- CN109311891B CN109311891B CN201780037131.9A CN201780037131A CN109311891B CN 109311891 B CN109311891 B CN 109311891B CN 201780037131 A CN201780037131 A CN 201780037131A CN 109311891 B CN109311891 B CN 109311891B
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- crystal
- crystalline
- crystalline composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D9/00—Crystallisation
- B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
Description
序号 | 2θ±0.2(°) | 相对强度(%) | 序号 | 2θ±0.2(°) | 相对强度(%) |
1 | 9.35 | 43.1 | 11 | 20.54 | 41.6 |
2 | 10.82 | 16.0 | 12 | 21.23 | 75.9 |
3 | 10.93 | 17.0 | 13 | 21.66 | 38.1 |
4 | 11.93 | 100.0 | 14 | 22.15 | 26.9 |
5 | 13.65 | 15.8 | 15 | 23.13 | 55.5 |
6 | 14.46 | 18.6 | 16 | 23.47 | 14.5 |
7 | 16.32 | 58.1 | 17 | 24.09 | 23.5 |
8 | 17.28 | 13.9 | 18 | 25.58 | 54.3 |
9 | 18.82 | 40.9 | 19 | 26.34 | 33.8 |
10 | 19.25 | 22.3 | 20 | 30.02 | 15.8 |
序号 | 2θ±0.2(°) | 相对强度(%) | 序号 | 2θ±0.2(°) | 相对强度(%) |
1 | 8.97 | 40.7 | 11 | 20.31 | 36.1 |
2 | 9.39 | 47.4 | 12 | 20.41 | 24.3 |
3 | 11.24 | 17.9 | 13 | 21.03 | 21.3 |
4 | 12.90 | 34.4 | 14 | 21.96 | 18.6 |
5 | 12.96 | 32.8 | 15 | 22.23 | 18.9 |
6 | 14.56 | 14.4 | 16 | 22.78 | 23.1 |
7 | 16.54 | 22.1 | 17 | 23.50 | 46.9 |
8 | 17.15 | 40.4 | 18 | 23.63 | 65.0 |
9 | 17.70 | 100.0 | 19 | 25.55 | 17.3 |
10 | 19.20 | 24.4 | ---- | ---- | ---- |
Claims (20)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610435947.4A CN107759600A (zh) | 2016-06-16 | 2016-06-16 | 作为jak抑制剂的吡咯并嘧啶化合物的结晶 |
CN2016104359474 | 2016-06-16 | ||
PCT/CN2017/088429 WO2017215630A1 (zh) | 2016-06-16 | 2017-06-15 | 作为jak抑制剂的吡咯并嘧啶化合物的结晶 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109311891A CN109311891A (zh) | 2019-02-05 |
CN109311891B true CN109311891B (zh) | 2020-09-04 |
Family
ID=60664302
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610435947.4A Pending CN107759600A (zh) | 2016-06-16 | 2016-06-16 | 作为jak抑制剂的吡咯并嘧啶化合物的结晶 |
CN201780037131.9A Active CN109311891B (zh) | 2016-06-16 | 2017-06-15 | 作为jak抑制剂的吡咯并嘧啶化合物的结晶 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610435947.4A Pending CN107759600A (zh) | 2016-06-16 | 2016-06-16 | 作为jak抑制剂的吡咯并嘧啶化合物的结晶 |
Country Status (11)
Country | Link |
---|---|
US (1) | US10626118B2 (zh) |
EP (1) | EP3473626B1 (zh) |
JP (1) | JP6986032B2 (zh) |
KR (1) | KR102523564B1 (zh) |
CN (2) | CN107759600A (zh) |
AU (1) | AU2017284702B2 (zh) |
CA (1) | CA3026602A1 (zh) |
ES (1) | ES2886910T3 (zh) |
RU (1) | RU2746045C2 (zh) |
TW (1) | TWI753918B (zh) |
WO (1) | WO2017215630A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107513069A (zh) * | 2016-06-16 | 2017-12-26 | 正大天晴药业集团股份有限公司 | 手性吡咯并嘧啶化合物的制备方法 |
CN107759600A (zh) | 2016-06-16 | 2018-03-06 | 正大天晴药业集团股份有限公司 | 作为jak抑制剂的吡咯并嘧啶化合物的结晶 |
AU2019413421A1 (en) | 2018-12-24 | 2021-08-12 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Treatment use of pyrrolopyrimidine compound, and solid pharmaceutical composition of pyrrolopyrimidine compound |
AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
CN114981272A (zh) * | 2020-03-09 | 2022-08-30 | 正大天晴药业集团股份有限公司 | 吡咯并嘧啶化合物的治疗噬血细胞综合征的用途 |
WO2022268083A1 (zh) * | 2021-06-21 | 2022-12-29 | 正大天晴药业集团股份有限公司 | 吡咯并嘧啶化合物及其药物组合物治疗慢性移植物抗宿主病的用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103214483A (zh) * | 2005-12-13 | 2013-07-24 | 因塞特公司 | 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶 |
CN105777754A (zh) * | 2014-12-16 | 2016-07-20 | 北京赛林泰医药技术有限公司 | 吡咯并嘧啶化合物 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2615091B1 (en) * | 2006-10-27 | 2016-01-20 | Signal Pharmaceuticals, LLC | Solid forms comprising 4-[9-(3S)-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9H-purin-2-ylamino]-trans-cyclohexan-1-ol, compositions thereof, and uses therewith |
EP3495369B1 (en) * | 2007-06-13 | 2021-10-27 | Incyte Holdings Corporation | Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile |
CL2009001884A1 (es) * | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
US20130310340A1 (en) * | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
CN105218548A (zh) * | 2014-06-09 | 2016-01-06 | 上海海和药物研究开发有限公司 | 一种新型杂环化合物及其制备方法和作为激酶抑制剂的用途 |
WO2016026975A1 (en) * | 2014-08-21 | 2016-02-25 | Ratiopharm Gmbh | Salt of (r)-3-(4-(7h-pyrrolo [2,3-d] pyrimidin-4-yl)-lh-pyrazol-l-yl)-3-cyclopentylpropanenitrile with benzenesulfonic acid |
CN107759600A (zh) | 2016-06-16 | 2018-03-06 | 正大天晴药业集团股份有限公司 | 作为jak抑制剂的吡咯并嘧啶化合物的结晶 |
-
2016
- 2016-06-16 CN CN201610435947.4A patent/CN107759600A/zh active Pending
-
2017
- 2017-06-15 RU RU2018145948A patent/RU2746045C2/ru active
- 2017-06-15 JP JP2018565295A patent/JP6986032B2/ja active Active
- 2017-06-15 US US16/310,369 patent/US10626118B2/en active Active
- 2017-06-15 ES ES17812741T patent/ES2886910T3/es active Active
- 2017-06-15 CA CA3026602A patent/CA3026602A1/en active Pending
- 2017-06-15 CN CN201780037131.9A patent/CN109311891B/zh active Active
- 2017-06-15 AU AU2017284702A patent/AU2017284702B2/en active Active
- 2017-06-15 TW TW106119959A patent/TWI753918B/zh active
- 2017-06-15 WO PCT/CN2017/088429 patent/WO2017215630A1/zh unknown
- 2017-06-15 EP EP17812741.1A patent/EP3473626B1/en active Active
- 2017-06-15 KR KR1020197001160A patent/KR102523564B1/ko active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103214483A (zh) * | 2005-12-13 | 2013-07-24 | 因塞特公司 | 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶 |
CN105777754A (zh) * | 2014-12-16 | 2016-07-20 | 北京赛林泰医药技术有限公司 | 吡咯并嘧啶化合物 |
Also Published As
Publication number | Publication date |
---|---|
AU2017284702A1 (en) | 2019-01-24 |
RU2018145948A (ru) | 2020-07-16 |
EP3473626A4 (en) | 2020-02-19 |
TW201800413A (zh) | 2018-01-01 |
CA3026602A1 (en) | 2017-12-21 |
JP6986032B2 (ja) | 2021-12-22 |
ES2886910T3 (es) | 2021-12-21 |
RU2018145948A3 (zh) | 2020-10-16 |
EP3473626A1 (en) | 2019-04-24 |
AU2017284702B2 (en) | 2021-05-06 |
CN109311891A (zh) | 2019-02-05 |
KR102523564B1 (ko) | 2023-04-19 |
RU2746045C2 (ru) | 2021-04-06 |
TWI753918B (zh) | 2022-02-01 |
WO2017215630A1 (zh) | 2017-12-21 |
KR20190017977A (ko) | 2019-02-20 |
JP2019521980A (ja) | 2019-08-08 |
CN107759600A (zh) | 2018-03-06 |
EP3473626B1 (en) | 2021-08-04 |
US10626118B2 (en) | 2020-04-21 |
US20190330215A1 (en) | 2019-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109311891B (zh) | 作为jak抑制剂的吡咯并嘧啶化合物的结晶 | |
CN107531682B (zh) | B-raf激酶抑制剂的马来酸盐、其结晶形式、制备方法和用途 | |
CN112979679B (zh) | 具有大环结构的含氟并杂环衍生物及其用途 | |
WO2021238817A1 (zh) | 大环jak抑制剂及其应用 | |
KR102531772B1 (ko) | Cdk4/6 키나아제 억제제를 타겟팅하는 결정형 | |
EP3812386A1 (en) | Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof | |
CN108676009B (zh) | 作为her2酪氨酸激酶抑制剂的嘧啶衍生物及其应用 | |
KR20190021345A (ko) | Egfr 저해제로 제공되는 아닐린 피리미딘 화합물의 결정 | |
CN111094314A (zh) | 含有葡糖苷酸衍生物jak抑制剂的前药及其制备方法和应用 | |
CN115667246A (zh) | 一种哒嗪类衍生物自由碱的晶型及其制备方法和应用 | |
CN113966332A (zh) | Cdk9抑制剂的多晶型物及其制法和用途 | |
CN111566101B (zh) | Cdk4/6抑制剂及其药学上可接受的盐和多晶型物及其应用 | |
US9688687B2 (en) | Polymorphic forms of icotinib phosphate and uses thereof | |
WO2018099451A1 (zh) | 化合物的晶型 | |
WO2014185797A1 (en) | Process for the preparation of high purity amorphous pemetrexed disodium and crystalline forms of n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3- d] pyrimidin-5-yl)ethyl] benzoyl]-l-glutamic acid | |
CN113493439B (zh) | 取代的丙烯酰胺衍生物及其组合物及用途 | |
TWI596098B (zh) | 埃克替尼馬來酸鹽的晶型及其用途 | |
CN115244054A (zh) | 次黄嘌呤化合物的晶体 | |
WO2021238818A1 (zh) | 一种大环jak抑制剂及其应用 | |
WO2023165570A1 (zh) | 环烷基或杂环基取代的杂芳基化合物及其组合物及用途 | |
CN117098761A (zh) | 咪唑并[4,5-d]哒嗪衍生物、其制备及其治疗性应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190603 Address after: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province Applicant after: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Applicant after: Lianyungang Runzhong Pharmaceutical Co.,Ltd. Applicant after: Capital Pharmaceutical Holdings (Beijing) Co., Ltd. Address before: 222062 Yuzhou South Road, Haizhou District, Lianyungang, Jiangsu 369 Applicant before: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Applicant before: Lianyungang Runzhong Pharmaceutical Co.,Ltd. Applicant before: Beijing Centaurus Biopharma Technology Co., Ltd. |
|
TA01 | Transfer of patent application right | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1260817 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder |
Address after: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province Patentee after: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd. Patentee after: LIANYUNGANG RUNZHONG PHARMACEUTICAL Co.,Ltd. Patentee after: Capital Pharmaceutical Holdings (Beijing) Co.,Ltd. Address before: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province Patentee before: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd. Patentee before: LIANYUNGANG RUNZHONG PHARMACEUTICAL Co.,Ltd. Patentee before: Shouyao holding (Beijing) Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder |